Bailey Heidi K, Kappy Michael S, Giller Roger H, Gralla Jane
University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA.
Pediatr Blood Cancer. 2008 Sep;51(3):405-9. doi: 10.1002/pbc.21634.
Hypothyroidism is a complication of hematopoietic stem cell transplantation (HSCT)1 that has been studied primarily in children after matched sibling bone marrow transplantation. Unrelated donors and umbilical cord blood (CB) are now used in transplantation, and hypothyroidism in these populations is undocumented. Children who underwent fractionated total body irradiation (fTBI) and received bone marrow or umbilical cord blood transplantation from siblings or unrelated donors were examined for hypothyroidism over time.
All children who received fTBI prior to allogeneic HSCT at The Children's Hospital (TCH), Denver between 1994 and 2002, and survived >1 year were included (N = 41 eligible; N = 33 met inclusion criteria). Probability of hypothyroidism was estimated by the Kaplan-Meier method and groups were compared using Cox's proportional hazards regression model.
Hypothyroidism developed in 52% of the children at a median time of 1.9 years (range 0.7-8.3 years). Primary compensated hypothyroidism was diagnosed in 94% of those affected. Children who received unrelated donor HSCT were 8.4 times more likely to develop hypothyroidism than those receiving matched sibling HSCT. Recipients of CB were 4.6 times more likely to have hypothyroidism than recipients of bone marrow.
There is a significant risk of developing hypothyroidism following fTBI, and allogeneic HSCT, that appears greater in recipients of unrelated donor HSCT and CB transplantation. Most of our patients who received BMT had sibling donors and the majority of CB transplants were from unrelated donors. It is difficult to determine which association is related to hypothyroidism, but the combination is significant.
甲状腺功能减退是造血干细胞移植(HSCT)的一种并发症,此前主要在同胞匹配骨髓移植后的儿童中进行研究。目前,非血缘供者和脐带血(CB)也用于移植,而这些人群中的甲状腺功能减退情况尚无记录。对接受分次全身照射(fTBI)并接受同胞或非血缘供者骨髓或脐带血移植的儿童进行了长期甲状腺功能减退检查。
纳入1994年至2002年期间在丹佛儿童医院(TCH)接受异基因HSCT前接受fTBI且存活超过1年的所有儿童(N = 41例符合条件;N = 33例符合纳入标准)。采用Kaplan-Meier法估计甲状腺功能减退的概率,并使用Cox比例风险回归模型对各组进行比较。
52%的儿童出现甲状腺功能减退,中位时间为1.9年(范围0.7 - 8.3年)。94%的受影响儿童被诊断为原发性代偿性甲状腺功能减退。接受非血缘供者HSCT的儿童发生甲状腺功能减退的可能性是接受同胞匹配HSCT儿童的8.4倍。接受CB的受者发生甲状腺功能减退的可能性是接受骨髓受者的4.6倍。
fTBI和异基因HSCT后发生甲状腺功能减退的风险显著,在非血缘供者HSCT和CB移植受者中似乎更高。我们大多数接受骨髓移植的患者有同胞供者,大多数CB移植来自非血缘供者。很难确定哪种关联与甲状腺功能减退有关,但两者的组合具有显著意义。